Viking Therapeutics: A Tempting Buyout Target in Biotech
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 11 hours ago
0mins
Source: NASDAQ.COM
- Weight Loss Drug Pipeline: Viking Therapeutics boasts a promising weight loss drug pipeline that capitalizes on the massive obesity market opportunity, yet it faces challenges from better-funded rivals that could impact its market position.
- Market Risk Assessment: While the stock presents substantial upside potential, investors must carefully evaluate risks due to a competitor's head start, especially when data, timing, and buyer interest are not fully aligned.
- Investment Recommendations: Despite being viewed as an attractive buyout target, Viking Therapeutics was not included in the Motley Fool analyst team's current list of top stocks to buy, indicating a cautious market sentiment regarding its future performance.
- Historical Return Comparison: The Motley Fool's Stock Advisor team highlights that their recommended stocks have achieved an average return of 922%, significantly outperforming the S&P 500's 208%, underscoring the importance of selecting the right investment targets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 39.960
Low
70.00
Averages
97.00
High
125.00
Current: 39.960
Low
70.00
Averages
97.00
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viking Therapeutics: A Tempting Buyout Target in Biotech
- Weight Loss Drug Pipeline: Viking Therapeutics boasts a promising weight loss drug pipeline that capitalizes on the massive obesity market opportunity, yet it faces challenges from better-funded rivals that could impact its market position.
- Market Risk Assessment: While the stock presents substantial upside potential, investors must carefully evaluate risks due to a competitor's head start, especially when data, timing, and buyer interest are not fully aligned.
- Investment Recommendations: Despite being viewed as an attractive buyout target, Viking Therapeutics was not included in the Motley Fool analyst team's current list of top stocks to buy, indicating a cautious market sentiment regarding its future performance.
- Historical Return Comparison: The Motley Fool's Stock Advisor team highlights that their recommended stocks have achieved an average return of 922%, significantly outperforming the S&P 500's 208%, underscoring the importance of selecting the right investment targets.
See More
Viking Therapeutics: A Tempting Buyout Target in Biotech
- Weight Loss Drug Pipeline Potential: Viking Therapeutics' weight loss drug pipeline presents enticing opportunities in the massive obesity market, potentially attracting buyer interest and enhancing the company's valuation and market competitiveness.
- Increased Competitive Risks: As better-funded rivals gain market traction, Viking's stock faces significant risks that could impact its future acquisition appeal and investor confidence, highlighting the need for strategic positioning.
- Importance of Data and Timing: While the potential upside for Viking is substantial, success hinges on the reliability of data, timing in the market, and buyer interest, with these factors directly influencing the company's stock performance.
- Market Price Fluctuations: The stock price as of June 26, 2026, shows a 2.80% increase, reflecting market optimism about Viking's future prospects, yet caution is warranted due to potential market volatility and uncertainties.
See More
Eli Lilly's Dominance in the Weight Loss Drug Market
- Market Share Growth: Eli Lilly has captured 60% of the U.S. GLP-1 drug market and 53% internationally, further solidifying its leadership position by launching the new oral weight loss drug Foundayo, which is expected to drive future sales growth.
- Surge in Sales: In the recent quarter, Lilly's weight loss products generated over $12 billion in sales, contributing to an overall sales increase of 56%, demonstrating its strong performance and profitability in the rapidly growing weight loss drug market.
- Promising R&D Pipeline: Lilly's robust pipeline in the weight loss drug sector includes the promising candidate retatrutide, currently in phase 3 trials, which has shown significant weight loss effects and is expected to provide strong support for the company's future growth.
- Evolving Competitive Landscape: While Lilly faces competition from companies like Viking Therapeutics, the strong demand for weight loss drugs indicates ample market space for multiple successful players, allowing Lilly to likely maintain its dominant market position.
See More
Vertex's $10B Crinetics Acquisition Sparks Biotech M&A Speculation
- M&A Activity Revived: Vertex's acquisition of Crinetics for $10 billion at $85 per share, representing a 102% premium, not only strengthens Vertex's foothold in rare endocrine diseases but also ignites speculation around VKTX and BCRX, leading to a broad rally in biotech stocks.
- VKTX's Positive Outlook: Viking Therapeutics saw a 9% stock increase post-announcement, with analysts projecting a 12-month target of $92.58, indicating a 120% upside, reflecting strong market confidence in its obesity drug VK2735, especially with upcoming Q3 maintenance data as a key catalyst.
- BCRX's Clear Benefits: BioCryst's shares rose 8%, with a 12-month target of $21.90 implying a 99% upside, bolstered by strong performance from its rare disease products Orladeyo and Navenibart, enhancing its competitive position in the market.
- Investor Sentiment Shift: Retail interest in VKTX and BCRX surged, with VKTX sentiment flipping from bearish to bullish as message volume jumped 400%, while BCRX sentiment turned extremely bullish from neutral, indicating strong investor interest and confidence in both stocks.
See More
Investment Outlook on Genetic Engineering and Weight Loss Innovations
- CRISPR Market Performance: CRISPR Therapeutics' stock is priced at $59.60, down 3.70% from the previous day, with a market cap of $6 billion; despite a 90% revenue decline due to the transition from one-time milestone payments to long-term commercial revenue, it highlights both challenges and potential in the gene therapy market.
- Viking Clinical Progress: Viking Therapeutics' stock is at $41.21, up 6.46%, yet it generated no revenue in FY 2025 with a net loss of approximately $359.6 million, reflecting high R&D costs in obesity and metabolic diseases and uncertainty in future commercialization.
- Risk and Dependency: CRISPR relies on Vertex Pharmaceuticals for 60% of its profits and faces intellectual property disputes that could impact financial sustainability, while Viking's dependence on Ligand Pharmaceuticals' licensing agreement poses a risk of halting its development programs, indicating vulnerabilities in both business models.
- Market Outlook Comparison: CRISPR's Casgevy treatment is globally approved, with projected sales exceeding $2 billion by 2029, while Viking is not expected to generate revenue until 2028; despite the vast GLP-1 drug market, Viking faces challenges in a competitive landscape.
See More
Viking Therapeutics Clinical Trial Outlook Analysis
- Market Competition Analysis: Viking Therapeutics' VK2735, a dual GLP-1/GIP agonist, faces significant competition from Eli Lilly and Novo Nordisk, whose drugs dominate the weight loss market, highlighting both challenges and opportunities for VK2735 in capturing market share.
- Unique Therapeutic Advantage: VK2735's dual formulation allows for rapid weight loss via injection followed by oral maintenance, achieving a notable 14.7% weight reduction in 13 weeks, which could appeal to patients seeking quicker results compared to competitors' offerings.
- Clinical Trial Progress: Viking is conducting a 19-week maintenance study, with phase 3 results for subcutaneous VK2735 expected in mid-2027 and oral dosing results anticipated in 2028, necessitating patience from investors as they await critical data.
- Investor Confidence and Risks: Despite a 20% discontinuation rate due to adverse events, market sentiment remains optimistic about VK2735's prospects, particularly if maintenance trial results are favorable, potentially attracting acquisition interest from larger pharmaceutical companies and enhancing the company's value.
See More
Viking Therapeutics: A Tempting Buyout Target in Biotech
- Weight Loss Drug Pipeline: Viking Therapeutics boasts a promising weight loss drug pipeline that capitalizes on the massive obesity market opportunity, yet it faces challenges from better-funded rivals that could impact its market position.
- Market Risk Assessment: While the stock presents substantial upside potential, investors must carefully evaluate risks due to a competitor's head start, especially when data, timing, and buyer interest are not fully aligned.
- Investment Recommendations: Despite being viewed as an attractive buyout target, Viking Therapeutics was not included in the Motley Fool analyst team's current list of top stocks to buy, indicating a cautious market sentiment regarding its future performance.
- Historical Return Comparison: The Motley Fool's Stock Advisor team highlights that their recommended stocks have achieved an average return of 922%, significantly outperforming the S&P 500's 208%, underscoring the importance of selecting the right investment targets.
See More
Viking Therapeutics: A Tempting Buyout Target in Biotech
- Weight Loss Drug Pipeline Potential: Viking Therapeutics' weight loss drug pipeline presents enticing opportunities in the massive obesity market, potentially attracting buyer interest and enhancing the company's valuation and market competitiveness.
- Increased Competitive Risks: As better-funded rivals gain market traction, Viking's stock faces significant risks that could impact its future acquisition appeal and investor confidence, highlighting the need for strategic positioning.
- Importance of Data and Timing: While the potential upside for Viking is substantial, success hinges on the reliability of data, timing in the market, and buyer interest, with these factors directly influencing the company's stock performance.
- Market Price Fluctuations: The stock price as of June 26, 2026, shows a 2.80% increase, reflecting market optimism about Viking's future prospects, yet caution is warranted due to potential market volatility and uncertainties.
See More
Eli Lilly's Dominance in the Weight Loss Drug Market
- Market Share Growth: Eli Lilly has captured 60% of the U.S. GLP-1 drug market and 53% internationally, further solidifying its leadership position by launching the new oral weight loss drug Foundayo, which is expected to drive future sales growth.
- Surge in Sales: In the recent quarter, Lilly's weight loss products generated over $12 billion in sales, contributing to an overall sales increase of 56%, demonstrating its strong performance and profitability in the rapidly growing weight loss drug market.
- Promising R&D Pipeline: Lilly's robust pipeline in the weight loss drug sector includes the promising candidate retatrutide, currently in phase 3 trials, which has shown significant weight loss effects and is expected to provide strong support for the company's future growth.
- Evolving Competitive Landscape: While Lilly faces competition from companies like Viking Therapeutics, the strong demand for weight loss drugs indicates ample market space for multiple successful players, allowing Lilly to likely maintain its dominant market position.
See More
Vertex's $10B Crinetics Acquisition Sparks Biotech M&A Speculation
- M&A Activity Revived: Vertex's acquisition of Crinetics for $10 billion at $85 per share, representing a 102% premium, not only strengthens Vertex's foothold in rare endocrine diseases but also ignites speculation around VKTX and BCRX, leading to a broad rally in biotech stocks.
- VKTX's Positive Outlook: Viking Therapeutics saw a 9% stock increase post-announcement, with analysts projecting a 12-month target of $92.58, indicating a 120% upside, reflecting strong market confidence in its obesity drug VK2735, especially with upcoming Q3 maintenance data as a key catalyst.
- BCRX's Clear Benefits: BioCryst's shares rose 8%, with a 12-month target of $21.90 implying a 99% upside, bolstered by strong performance from its rare disease products Orladeyo and Navenibart, enhancing its competitive position in the market.
- Investor Sentiment Shift: Retail interest in VKTX and BCRX surged, with VKTX sentiment flipping from bearish to bullish as message volume jumped 400%, while BCRX sentiment turned extremely bullish from neutral, indicating strong investor interest and confidence in both stocks.
See More
Investment Outlook on Genetic Engineering and Weight Loss Innovations
- CRISPR Market Performance: CRISPR Therapeutics' stock is priced at $59.60, down 3.70% from the previous day, with a market cap of $6 billion; despite a 90% revenue decline due to the transition from one-time milestone payments to long-term commercial revenue, it highlights both challenges and potential in the gene therapy market.
- Viking Clinical Progress: Viking Therapeutics' stock is at $41.21, up 6.46%, yet it generated no revenue in FY 2025 with a net loss of approximately $359.6 million, reflecting high R&D costs in obesity and metabolic diseases and uncertainty in future commercialization.
- Risk and Dependency: CRISPR relies on Vertex Pharmaceuticals for 60% of its profits and faces intellectual property disputes that could impact financial sustainability, while Viking's dependence on Ligand Pharmaceuticals' licensing agreement poses a risk of halting its development programs, indicating vulnerabilities in both business models.
- Market Outlook Comparison: CRISPR's Casgevy treatment is globally approved, with projected sales exceeding $2 billion by 2029, while Viking is not expected to generate revenue until 2028; despite the vast GLP-1 drug market, Viking faces challenges in a competitive landscape.
See More
Viking Therapeutics Clinical Trial Outlook Analysis
- Market Competition Analysis: Viking Therapeutics' VK2735, a dual GLP-1/GIP agonist, faces significant competition from Eli Lilly and Novo Nordisk, whose drugs dominate the weight loss market, highlighting both challenges and opportunities for VK2735 in capturing market share.
- Unique Therapeutic Advantage: VK2735's dual formulation allows for rapid weight loss via injection followed by oral maintenance, achieving a notable 14.7% weight reduction in 13 weeks, which could appeal to patients seeking quicker results compared to competitors' offerings.
- Clinical Trial Progress: Viking is conducting a 19-week maintenance study, with phase 3 results for subcutaneous VK2735 expected in mid-2027 and oral dosing results anticipated in 2028, necessitating patience from investors as they await critical data.
- Investor Confidence and Risks: Despite a 20% discontinuation rate due to adverse events, market sentiment remains optimistic about VK2735's prospects, particularly if maintenance trial results are favorable, potentially attracting acquisition interest from larger pharmaceutical companies and enhancing the company's value.
See More
